{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:43:48Z","timestamp":1791211428739,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Qatar Research Development and Innovation Council","award":["ARG02-0402-240119"],"award-info":[{"award-number":["ARG02-0402-240119"]}]},{"name":"Qatar Research Development and Innovation Council","award":["ARG02-0402-240119"],"award-info":[{"award-number":["ARG02-0402-240119"]}]},{"name":"Qatar Research Development and Innovation Council","award":["ARG02-0402-240119"],"award-info":[{"award-number":["ARG02-0402-240119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19168-3","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:36:14Z","timestamp":1759923374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-9688","authenticated-orcid":false,"given":"Layan","family":"Sukik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-6968","authenticated-orcid":false,"given":"Hiam","family":"Chemaitelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-6657","authenticated-orcid":false,"given":"Houssein H.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A.","family":"Al Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Al-Kanaani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jeremijenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvar Hassan","family":"Kaleeckal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Nizar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyazuddin Mohammad","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan F.","family":"Abdul-Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ghaith","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel A.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad Eid","family":"Al-Romaihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Al-Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullatif","family":"Al-Khal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"19168_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N Engl. J. Med."},{"key":"19168_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl. J. Med. 384, 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2021).","journal-title":"N Engl. J. Med."},{"key":"19168_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. National study group for Covid vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl. J. Med. 385, 187\u2013189. https:\/\/doi.org\/10.1056\/NEJMc2104974 (2021).","journal-title":"N Engl. J. Med."},{"key":"19168_CR4","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","volume":"27","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat. Med. 27, 1614\u20131621. https:\/\/doi.org\/10.1038\/s41591-021-01446-y (2021).","journal-title":"Nat. Med."},{"key":"19168_CR5","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J. et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl. J. Med. 386, 1804\u20131816. https:\/\/doi.org\/10.1056\/NEJMoa2200797 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR6","unstructured":"VIEW-hub by IVAC. Vaccine effectiveness studies. COVID-19 data. Accessed on March 1, (2025). https:\/\/view-hub.org\/covid-19\/effectiveness-studies"},{"key":"19168_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944. https:\/\/doi.org\/10.1016\/S0140-6736(22)00152-0 (2022).","journal-title":"Lancet"},{"key":"19168_CR8","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl. J. Med. 385, e83. https:\/\/doi.org\/10.1056\/NEJMoa2114114 (2021).","journal-title":"N Engl. J. Med."},{"key":"19168_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMc2119432","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J., Chemaitelly, H. & Bertollini, R. National study group for Covid vaccination. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. N Engl. J. Med. 386, 1091\u20131093. https:\/\/doi.org\/10.1056\/NEJMc2119432 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(22)00277-X","volume":"399","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. & Abu-Raddad, L. J. Waning effectiveness of COVID-19 vaccines. Lancet 399, 771\u2013773. https:\/\/doi.org\/10.1016\/S0140-6736(22)00277-X (2022).","journal-title":"Lancet"},{"key":"19168_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361\u2013379. https:\/\/doi.org\/10.1038\/s41579-023-00878-2 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"19168_CR12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/s41564-023-01504-w","volume":"8","author":"C Roemer","year":"2023","unstructured":"Roemer, C. et al. SARS-CoV-2 evolution in the Omicron era. Nat. Microbiol. 8, 1952\u20131959. https:\/\/doi.org\/10.1038\/s41564-023-01504-w (2023).","journal-title":"Nat. Microbiol."},{"key":"19168_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41591-022-01836-w","volume":"28","author":"L Subissi","year":"2022","unstructured":"Subissi, L. et al. An early warning system for emerging SARS-CoV-2 variants. Nat. Med. 28, 1110\u20131115. https:\/\/doi.org\/10.1038\/s41591-022-01836-w (2022).","journal-title":"Nat. Med."},{"key":"19168_CR14","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1038\/s41467-022-30895-3","volume":"13","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat. Commun. 13, 3082. https:\/\/doi.org\/10.1038\/s41467-022-30895-3 (2022).","journal-title":"Nat. Commun."},{"key":"19168_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41586-024-08511-9","volume":"639","author":"H Chemaitelly","year":"2025","unstructured":"Chemaitelly, H. et al. Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron. Nature 639, 1024\u20131031. https:\/\/doi.org\/10.1038\/s41586-024-08511-9 (2025).","journal-title":"Nature"},{"key":"19168_CR16","unstructured":"World Health Organization (WHO). Living guidance for clinical management of COVID-19. (2023). Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2021-2. Accessed on: February 27, 2023."},{"key":"19168_CR17","unstructured":"World Health Organization (WHO). International guidelines for certification and classification (coding) of COVID-19 as cause of death. (2023). Available from: https:\/\/www.who.int\/publications\/m\/item\/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death. Accessed on: February 27, (2023)."},{"key":"19168_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"19168_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang, S. V. et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 1376\u20131385. https:\/\/doi.org\/10.1001\/jama.2023.4221 (2023).","journal-title":"JAMA"},{"key":"19168_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl. J. Med. 387, 21\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2203965 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(23)00058-0","volume":"23","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect. Dis. 23, 816\u2013827. https:\/\/doi.org\/10.1016\/S1473-3099(23)00058-0 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"19168_CR22","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1016\/S2666-5247(22)00287-7","volume":"3","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in qatar: a retrospective cohort study. Lancet Microbe. 3, e944\u2013e955. https:\/\/doi.org\/10.1016\/S2666-5247(22)00287-7 (2022).","journal-title":"Lancet Microbe"},{"key":"19168_CR23","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa2210058","volume":"387","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Covid-19 vaccine protection among children and adolescents in Qatar. N Engl. J. Med. 387, 1865\u20131876. https:\/\/doi.org\/10.1056\/NEJMoa2210058 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR24","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 Omicron XBB* infections. J. Travel Med. 30 https:\/\/doi.org\/10.1093\/jtm\/taad106 (2023).","DOI":"10.1093\/jtm\/taad106"},{"key":"19168_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMc2117933","volume":"386","author":"LJ Abu-Raddad","year":"2022","unstructured":"Abu-Raddad, L. J., Chemaitelly, H. & Bertollini, R. National study group for Covid vaccination. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. N Engl. J. Med. 386, 799\u2013800. https:\/\/doi.org\/10.1056\/NEJMc2117933 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR26","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1038\/s41598-021-85428-7","volume":"11","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci. Rep. 11, 6233. https:\/\/doi.org\/10.1038\/s41598-021-85428-7 (2021).","journal-title":"Sci. Rep."},{"key":"19168_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijid.2023.09.005","volume":"136","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in qatar: a National cohort study. Int. J. Infect. Dis. 136, 81\u201390. https:\/\/doi.org\/10.1016\/j.ijid.2023.09.005 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"19168_CR28","doi-asserted-by":"publisher","unstructured":"AlNuaimi, A. A. et al. All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic. BMJ Glob Health. 8 https:\/\/doi.org\/10.1136\/bmjgh-2023-012291 (2023).","DOI":"10.1136\/bmjgh-2023-012291"},{"key":"19168_CR29","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jama.2021.19623","volume":"326","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J. et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA 326, 1930\u20131939. https:\/\/doi.org\/10.1001\/jama.2021.19623 (2021).","journal-title":"JAMA"},{"key":"19168_CR30","doi-asserted-by":"publisher","first-page":"eadh0761","DOI":"10.1126\/sciadv.adh0761","volume":"9","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. History of primary-series and booster vaccination and protection against Omicron reinfection. Sci. Adv. 9, eadh0761. https:\/\/doi.org\/10.1126\/sciadv.adh0761 (2023).","journal-title":"Sci. Adv."},{"key":"19168_CR31","doi-asserted-by":"publisher","first-page":"e13224","DOI":"10.1111\/irv.13224","volume":"17","author":"MA Mahmoud","year":"2023","unstructured":"Mahmoud, M. A. et al. SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A National cohort study. Influenza Other Respir Viruses. 17, e13224. https:\/\/doi.org\/10.1111\/irv.13224 (2023).","journal-title":"Influenza Other Respir Viruses"},{"key":"19168_CR32","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J. Travel Med. 29 https:\/\/doi.org\/10.1093\/jtm\/taac109 (2022).","DOI":"10.1093\/jtm\/taac109"},{"key":"19168_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2211055","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Immune imprinting and protection against repeat reinfection with SARS-CoV-2. N Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2211055 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR34","doi-asserted-by":"publisher","first-page":"e13357","DOI":"10.1111\/irv.13357","volume":"18","author":"H Chemaitelly","year":"2024","unstructured":"Chemaitelly, H. et al. BNT162b2 versus mRNA-1273 vaccines: comparative analysis of long-term protection against SARS-CoV-2 infection and severe COVID-19 in Qatar. Influenza Other Respir Viruses. 18, e13357. https:\/\/doi.org\/10.1111\/irv.13357 (2024).","journal-title":"Influenza Other Respir Viruses"},{"key":"19168_CR35","doi-asserted-by":"publisher","first-page":"e000479","DOI":"10.1136\/bmjph-2023-000479","volume":"1","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Turning point in COVID-19 severity and fatality during the pandemic: a National cohort study in Qatar. BMJ Public. Health. 1, e000479. https:\/\/doi.org\/10.1136\/bmjph-2023-000479 (2023).","journal-title":"BMJ Public. Health"},{"key":"19168_CR36","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMc2200133","volume":"386","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Protection against the Omicron variant from previous SARS-CoV-2 infection. N Engl. J. Med. 386, 1288\u20131290. https:\/\/doi.org\/10.1056\/NEJMc2200133 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR37","doi-asserted-by":"publisher","first-page":"05005","DOI":"10.7189\/jogh.11.05005","volume":"11","author":"HH Ayoub","year":"2021","unstructured":"Ayoub, H. H. et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the National response to COVID-19. J. Glob Health. 11, 05005. https:\/\/doi.org\/10.7189\/jogh.11.05005 (2021).","journal-title":"J. Glob Health"},{"key":"19168_CR38","doi-asserted-by":"publisher","unstructured":"Coyle, P. V. et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience 24, 102646. https:\/\/doi.org\/10.1016\/j.isci.2021.102646 (2021).","DOI":"10.1016\/j.isci.2021.102646"},{"key":"19168_CR39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3201\/eid2705.204365","volume":"27","author":"A Jeremijenko","year":"2021","unstructured":"Jeremijenko, A. et al. Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. Emerg. Infect. Dis. 27, 1343\u20131352. https:\/\/doi.org\/10.3201\/eid2705.204365 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"19168_CR40","doi-asserted-by":"publisher","first-page":"ofab221","DOI":"10.1093\/ofid\/ofab221","volume":"8","author":"MH Al-Thani","year":"2021","unstructured":"Al-Thani, M. H. et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. Open. Forum Infect. Dis. 8, ofab221. https:\/\/doi.org\/10.1093\/ofid\/ofab221 (2021).","journal-title":"Open. Forum Infect. Dis."},{"key":"19168_CR41","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1038\/s41467-022-32363-4","volume":"13","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nat. Commun. 13, 4675. https:\/\/doi.org\/10.1038\/s41467-022-32363-4 (2022).","journal-title":"Nat. Commun."},{"key":"19168_CR42","doi-asserted-by":"publisher","first-page":"112911","DOI":"10.1016\/j.envres.2022.112911","volume":"209","author":"S Pilz","year":"2022","unstructured":"Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R. & Ioannidis, J. P. A. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ. Res. 209, 112911. https:\/\/doi.org\/10.1016\/j.envres.2022.112911 (2022).","journal-title":"Environ. Res."},{"key":"19168_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/01632787211047932","volume":"44","author":"N Kojima","year":"2021","unstructured":"Kojima, N., Shrestha, N. K. & Klausner, J. D. A systematic review of the protective effect of prior SARS-CoV-2 infection on repeat infection. Eval Health Prof. 44, 327\u2013332. https:\/\/doi.org\/10.1177\/01632787211047932 (2021).","journal-title":"Eval Health Prof."},{"key":"19168_CR44","doi-asserted-by":"publisher","first-page":"1363045","DOI":"10.3389\/fmed.2024.1363045","volume":"11","author":"H Chemaitelly","year":"2024","unstructured":"Chemaitelly, H. et al. Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation. Front. Med. (Lausanne). 11, 1363045. https:\/\/doi.org\/10.3389\/fmed.2024.1363045 (2024).","journal-title":"Front. Med. (Lausanne)"},{"key":"19168_CR45","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in israel: an observational study. Lancet 398, 2093\u20132100. https:\/\/doi.org\/10.1016\/S0140-6736(21)02249-2 (2021).","journal-title":"Lancet"},{"key":"19168_CR46","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun. Stat-Simul C. 38, 1228\u20131234. https:\/\/doi.org\/10.1080\/03610910902859574 (2009).","journal-title":"Commun. Stat-Simul C"},{"key":"19168_CR47","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1002\/sim.5879","volume":"32","author":"A Sjolander","year":"2013","unstructured":"Sjolander, A. & Greenland, S. Ignoring the matching variables in cohort studies - when is it valid and why? Stat. Med. 32, 4696\u20134708. https:\/\/doi.org\/10.1002\/sim.5879 (2013).","journal-title":"Stat. Med."},{"key":"19168_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41467-023-35815-7","volume":"14","author":"HF Tseng","year":"2023","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat. Commun. 14, 189. https:\/\/doi.org\/10.1038\/s41467-023-35815-7 (2023).","journal-title":"Nat. Commun."},{"key":"19168_CR49","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","volume":"323","author":"MJ Stensrud","year":"2020","unstructured":"Stensrud, M. J. & Hernan, M. A. Why test for proportional hazards? JAMA 323, 1401\u20131402. https:\/\/doi.org\/10.1001\/jama.2020.1267 (2020).","journal-title":"JAMA"},{"key":"19168_CR50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1056\/NEJMc2209306","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 subvariants. N Engl. J. Med. 387, 1620\u20131622. https:\/\/doi.org\/10.1056\/NEJMc2209306 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR51","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJMc2214114","volume":"388","author":"H Chemaitelly","year":"2023","unstructured":"Chemaitelly, H. et al. Protection against reinfection with the Omicron BA.2.75 subvariant. N Engl. J. Med. 388, 665\u2013667. https:\/\/doi.org\/10.1056\/NEJMc2214114 (2023).","journal-title":"N Engl. J. Med."},{"key":"19168_CR52","doi-asserted-by":"publisher","unstructured":"Chemaitelly, H. et al. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant. J. Travel Med. 31 https:\/\/doi.org\/10.1093\/jtm\/taae053 (2024).","DOI":"10.1093\/jtm\/taae053"},{"key":"19168_CR53","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl. J. Med. 386, 1532\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa2119451 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR54","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656. https:\/\/doi.org\/10.1038\/s41586-021-04387-1 (2022).","journal-title":"Nature"},{"key":"19168_CR55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMc2206576","volume":"387","author":"NP Hachmann","year":"2022","unstructured":"Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl. J. Med. 387, 86\u201388. https:\/\/doi.org\/10.1056\/NEJMc2206576 (2022).","journal-title":"N Engl. J. Med."},{"key":"19168_CR56","doi-asserted-by":"publisher","first-page":"100564","DOI":"10.1016\/j.jvacx.2024.100564","volume":"20","author":"G Bredholt","year":"2024","unstructured":"Bredholt, G. et al. Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. Vaccine X. 20, 100564. https:\/\/doi.org\/10.1016\/j.jvacx.2024.100564 (2024).","journal-title":"Vaccine X"},{"key":"19168_CR57","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s43587-024-00644-w","volume":"4","author":"B Dallan","year":"2024","unstructured":"Dallan, B. et al. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19. Nat. Aging. 4, 1121\u20131136. https:\/\/doi.org\/10.1038\/s43587-024-00644-w (2024).","journal-title":"Nat. Aging"},{"key":"19168_CR58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417\u2013422. https:\/\/doi.org\/10.1038\/s41586-021-03739-1 (2021).","journal-title":"Nature"},{"key":"19168_CR59","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/infdis\/jiab592","volume":"225","author":"MA Brockman","year":"2022","unstructured":"Brockman, M. A. et al. Reduced magnitude and durability of humoral immune responses to covid-19 Mrna vaccines among older adults. J. Infect. Dis. 225, 1129\u20131140. https:\/\/doi.org\/10.1093\/infdis\/jiab592 (2022).","journal-title":"J. Infect. Dis."},{"key":"19168_CR60","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/cid\/ciab381","volume":"73","author":"L Muller","year":"2021","unstructured":"Muller, L. et al. Age-dependent immune response to the biontech\/pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin. Infect. Dis. 73, 2065\u20132072. https:\/\/doi.org\/10.1093\/cid\/ciab381 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"19168_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/10408363.2022.2038539","volume":"59","author":"KI Notarte","year":"2022","unstructured":"Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab. Sci. 59, 373\u2013390. https:\/\/doi.org\/10.1080\/10408363.2022.2038539 (2022).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"19168_CR62","doi-asserted-by":"publisher","first-page":"e3465","DOI":"10.1002\/dmrr.3465","volume":"38","author":"M Watanabe","year":"2022","unstructured":"Watanabe, M. et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab. Res. Rev. 38, e3465. https:\/\/doi.org\/10.1002\/dmrr.3465 (2022).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"19168_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.026","author":"L Sukik","year":"2024","unstructured":"Sukik, L. et al. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient. Vaccine https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.026 (2024).","journal-title":"Vaccine"},{"key":"19168_CR64","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41422-023-00781-8","volume":"33","author":"B Gao","year":"2023","unstructured":"Gao, B. et al. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection. Cell. Res. 33, 258\u2013261. https:\/\/doi.org\/10.1038\/s41422-023-00781-8 (2023).","journal-title":"Cell. Res."},{"key":"19168_CR65","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41586-022-05644-7","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529. https:\/\/doi.org\/10.1038\/s41586-022-05644-7 (2023).","journal-title":"Nature"},{"key":"19168_CR66","doi-asserted-by":"publisher","unstructured":"Reynolds, C. J. et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science, eabq1841. https:\/\/doi.org\/10.1126\/science.abq1841 (2022).","DOI":"10.1126\/science.abq1841"},{"key":"19168_CR67","doi-asserted-by":"publisher","unstructured":"Roltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025\u20131040 e1014. https:\/\/doi.org\/10.1016\/j.cell.2022.01.018 (2022).","DOI":"10.1016\/j.cell.2022.01.018"},{"key":"19168_CR68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijid.2023.03.022","volume":"131","author":"K Bodner","year":"2023","unstructured":"Bodner, K., Irvine, M. A., Kwong, J. C. & Mishra, S. Observed negative vaccine effectiveness could be the Canary in the coal mine for biases in observational COVID-19 studies. Int. J. Infect. Dis. 131, 111\u2013114. https:\/\/doi.org\/10.1016\/j.ijid.2023.03.022 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"19168_CR69","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","volume":"5","author":"J Mossong","year":"2008","unstructured":"Mossong, J. et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5, e74. https:\/\/doi.org\/10.1371\/journal.pmed.0050074 (2008).","journal-title":"PLoS Med."},{"key":"19168_CR70","doi-asserted-by":"publisher","unstructured":"Abu-Raddad, L. J. et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J. Travel Med. 28 https:\/\/doi.org\/10.1093\/jtm\/taab083 (2021).","DOI":"10.1093\/jtm\/taab083"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19168-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:36:16Z","timestamp":1759923376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19168-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19168"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19168-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35179"}}